Effects of mogamulizumab in adult T-cell leukemia/lymphoma in clinical practice.
OBJECTIVE
The efficacy of mogamulizumab in adult T-cell leukemia/lymphoma (ATLL) was reported in a previous phase 2 study. Compared with patients in clinical trials, however, most patients in real-life settings have demonstrated worse outcomes.


METHODS
We retrospectively analyzed 96 patients with relapsed/refractory ATLL who received mogamulizumab treatment.


RESULTS
Relapsed/refractory ATLL patients with a median age of 70 years received a median of five courses of mogamulizumab. Hematologic toxicity and skin rash were the most common adverse events, and both were manageable. Of 96 patients, 87 were evaluable for efficacy. The overall response rate was 36%, and the median progression-free survival (PFS) and overall survival (OS) from the start of mogamulizumab therapy were 1.8 and 4.0 months, respectively. Of the original 96 patients, only 25 fulfilled the inclusion criteria of the phase 2 study. Those who met the criteria demonstrated longer median PFS and OS durations of 2.7 and 8.5 months, respectively. The median OS from diagnosis in relapsed/refractory ATLL patients receiving mogamulizumab was 12 months, longer than the 5.8 months in a historical cohort without mogamulizumab.


CONCLUSIONS
In clinical practice, mogamulizumab exhibited antitumor activity in patients with relapsed/refractory ATLL, with an acceptable toxicity profile. Mogamulizumab therapy improved the OS of ATLL patients.
Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Masaaki
http://orcid.org/0000-0001-5481-3451
M
Sekine
Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Yoko
Y
Kubuki
Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Takuro
T
Kameda
Koga General Hospital, Miyazaki, Japan.
Masanori
M
Takeuchi
Miyazaki Prefectural Nobeoka Hospital, Nobeoka, Japan.
Takanori
T
Toyama
Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan.
Noriaki
N
Kawano
Miyakonojo Medical Center, Miyakonojo, Japan.
Kouichi
K
Maeda
Fujimoto Genral Hospital, Miyakonojo, Japan.
Seiichi
S
Sato
Miyazaki Aisenkai Nichinan hospital, Nichinan, Japan.
Junzo
J
Ishizaki
Koga General Hospital, Miyazaki, Japan.
Hiroshi
H
Kawano
Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Ayako
A
Kamiunten
Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Keiichi
K
Akizuki
Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Yuki
Y
Tahira
Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Haruko
H
Shimoda
Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Kotaro
K
Shide
Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Tomonori
T
Hidaka
Department of Laboratory Medicine, Kawasaki Medical School, Kurashiki, Japan.
Akira
A
Kitanaka
Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan.
Kiyoshi
K
Yamashita
Koga General Hospital, Miyazaki, Japan.
Hitoshi
H
Matsuoka
Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Kazuya
K
Shimoda
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000074322:Antineoplastic Agents, Immunological / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D019233:Retreatment; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
D061067:Antibodies, Monoclonal, Humanized; D000074322:Antineoplastic Agents, Immunological; C549035:mogamulizumab
CC chemokine receptor 4; adult T-cell leukemia/lymphoma; antibody therapy; mogamulizumab; retrospective